Pneumocystis jirovecii pneumonia in systemic lupus erythematosus from Southern Taiwan

Journal of Clinical Rheumatology

Volumn 19, Issue 5, 2013, Pages 252-258

  Weng, Chia Tse ^a   Liu, Ming Fei ^a   Weng, Meng Yu ^a   Lee, Nan Yao ^b   Wang, Ming Chang ^b   Lin, Wei Chieh ^b   Ou, Chih Ying ^b   Lai, Wu Wei ^c   Hsu, Shiang Chin ^c   Chao, Sheau Chiou ^c   Chung, Ta Jung ^c   Lee, Chung Ta ^c   Shieh, Chi Chang ^c   Wang, Jiu Yao ^c   Wang, Chrong Reen ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b Dou Liou Branch   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

biologics; immunosuppressants; Pneumocystis jirovecii pneumonia; prophylactic antibiotics; systemic lupus erythematosus

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG LAVAGE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MALE; MORTALITY; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPUTUM ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TAIWAN;

ADULT; BIOPSY; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RISK FACTORS; SPUTUM; TAIWAN;

EID: 84881477483     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31829d5017     Document Type: Article

References (53)

1. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487-2498.
2. Catherinot E, Lanternier F, Bougnoux ME, et al. Pneumocystis jirovecii pneumonia. Infect Dis Clin North Am. 2010;24:107-138.
3. Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2010;6:644-652.
4. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187-198.
5. Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum. 1996;39:1475-1482.
6. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42:780-789.
7. Hahn BH, McMathon MA, Wilkinson A, et al. American College of Rheumatology Guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797-808.
8. Teichmann LL, Woenckhaus M, Vogel C, et al. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology. 2008;47:1256-1257.
9. Hugle B, Solomon M, Harvey E, et al. Pneumocystis jirovecii pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res. 2010;62:1661-1664.
10. Tsai MJ, Chou CW, Lin FC, et al. Pneumocystis carinii pneumonia in patients with systemic lupus erythematosus after rituximab therapy. Lupus. 2012;21:914-918.
11. Weng CT, Chung TJ, Liu MF, et al. A retrospective study of pulmonary infarction in patients with systemic lupus erythematosus from southern Taiwan. Lupus. 2011;20:876-885.
12. Wang CR, Liu CC, Li YH, et al. Adult-onset acute rheumatic fever: possible resurgence in southern Taiwan. J Clin Rheumatol. 2005;11:146-149.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
14. Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol. 2002;29:288-291.
15. Robberts FJ, Liebowitz LD, Chalkley LJ. Polymerase chain reaction detection of Pneumocystis jirovecii: evaluation of 9 assays. Diagn Microbiol Infect Dis. 2007;58:385-392.
16. Mekinian A, Durand-Joly I, Hatron PY, et al. Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology. 2011;50:569-577.
17. Gupta D, Zachariah A, Roppelt H, et al. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature. J Clin Rheumatol. 2008;14:267-272.
18. Liam CK, Wang F. Pneumocystis carinii pneumonia in patients with systemic lupus erythematosus. Lupus. 1992;1:379-385.
19. Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21:246-251.
20. Kadoya A, Okada J, Iikuni Y, et al. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol. 1996;23:1186-1188.
21. Kim WU, Min JK, Lee SH, et al. Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol. 1999;17:539-545.
22. Mok CC, Lee KW, Ho CT, et al. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology. 2000;39:399-406.
23. Noël V, Lortholary O, Casassus P, et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis. 2001;60:1141-1144.
24. Gladman DD, Hussain F, Ibanẽz D, et al. The nature and outcome of infection in systemic lupus erythematosus. Lupus. 2002;11:234-239.
25. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971-980.
26. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219-2228.
27. Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med. 2006;119:355.e25-e33.
28. Li J, Huang XM, Fang WG, et al. Pneumocystis carinii pneumonia in patients with connective tissue disease. J Clin Rheumatol. 2006;12:114-117.
29. Bosch X, Guilabert A, Pallarés L, et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus. 2006;15:584-589.
30. Narata R, Wangkaew S, Kasitanon N, et al. Community-acquired pneumonia in Thai patients with systemic lupus erythematosus. Southeast Asian J Trop Med Public Health. 2007;38:528-536.
31. Quadrelli SA, Alvarez C, Arce SC, et al. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus. 2009;18:1053-1060.
32. Vananuvat P, Suwannalai P, Sungkanuparph S, et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum. 2011;41:497-502.
33. Boiselle PM, Crans CA Jr, Kaplan MA. The changing face of Pneumocystis carinii pneumonia in AIDS patients. AJR. 1999;172:1301-1309.
34. Horowitz DM, Furie RA. Abetimus sodium: a medication for the prevention of lupus nephritis flares. Expert Opin Pharmacother. 2009;10:1501-1507.
35. Engel P, Gómez-Puerta JA, Ramos-Casals M, et al. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev. 2011;63:127-156.
36. Petri M. Infection in systemic lupus erythematosus. Rheum Dis Clin North Am. 1998;24:423-456.
37. Ruskin J, Remington JS. The compromised host and infection. I. Pneumocystis carinii pneumonia. JAMA. 1967;202:1070-1074.
38. Jakes RW, Bae SC, Louthrenoo W, et al. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res. 2012;64:159-168.
39. Wang CR, Chuang CY, Chen CY. Drug allergy in Chinese patients with systemic lupus erythematosus. J Rheumatol. 1993;20:399-400.
40. Benfield T, Atzori C, Miller RF, et al. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr. 2008;48:63-67.
41. Wallace DJ. Advances in drug therapy for systemic lupus erythematosus. BMC Med. 2010;8:77.
42. Kelesidis T, Daikos G, Boumpas D, et al. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2011;15:e2-e16.
43. Harmsen AG, Stankiewicz M. Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp Med. 1990;172:937-945.
44. Phair J, Munõz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med. 1990;322:161-165.
45. Marcotte H, Levesque D, Delanay K, et al. Pneumocystis carinii infection in transgenic B cellYdeficient mice. J Infect Dis. 1996;173:1034-1037.
46. Lund FE, Hollifield M, Schuer K, et al. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol. 2006;176:6147-6154.
47. Dall'Era M. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2011;23:454-458.
48. Hanvesakul R, Kubal C, Jham S, et al. Increased incidence of infections following the late introduction of mycophenolate mofetil in renal transplant recipients. Nephrol Dial Transplant. 2008;23:4049-4053.
49. Ritter ML, Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis. 2009;11:290-297.
50. Arichi N, Kishikawa H, Mitsui Y, et al. Cluster outbreak of Pneumocystis pneumonia among kidney transplant patients within a single center. Transplant Proc. 2009;41:170-172.
51. Kermani TA, Ytterberg SR, Warrington KJ. Pneumocystis pneumonia in giant cell arteritis: a case series. Arthritis Care Res. 2011;63:761-765.
52. Gómez-Puerta JA, Quintana LF, Stone JH, et al. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Autoimmun Rev. 2012;11:646-652.
53. Cettomai D, Gelber AC, Christopher-Stine L. A survey of rheumatologists' practice for prescribing Pneumocystis prophylaxis. J Rheumatol. 2010;37:792-799.